Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by fairweather1on Nov 01, 2014 10:33am

157 Views

Post# 23084815

RE:Is this dead?

I'm guessing this is such a one trick pony at this stage that there is nothing to discuss until we get news about STS.

The company's journey has been tortuous. One would expect the news to be either good or bad (ie: no middle ground), except that that is sort of where the last trial data left us...wondering.

On it goes...

Bullboard Posts

Hyundai partners with BlackBerry for next-gen digital cockpit platform